Validate Your Expertise in PK/PD NCA Analysis Through Certara Professional Certification By Maria Saluta
Certara Supports the Not-for-profit Biotechnology Company Medicines Development for Global Health (MDGH) on the FDA New Drug Approval of Moxidectin for the Treatment of River Blindness (Onchocerciasis), a Neglected Tropical Disease Read more
Certara Launches Version 8.1 of its Industry-leading Phoenix PK/PD Modeling and Simulation Software; Introduces Professional Certification Program Read more
Certara Scientists to Present Model-informed Drug Development, Systems Pharmacology and MBMA Advances at PAGE 2018 Read more
How to Use a Reference-scaled Average Bioequivalence Approach for Narrow Therapeutic Index Drugs Read more
Leveraging In Vitro Data to Improve Prediction of Drug Clearance in Renally-impaired Populations Read more
Application of Tracer Kinetics in Drug Development: A Valuable but Underused Tool in Clinical Pharmacology Read more
